Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 22, 2009, Noramco Inc., Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, GA 30601, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Tapentadol Start Printed Page 29720(9780), a basic class of controlled substance listed in schedule II.
The company plans to bulk manufacture the above listed controlled substance for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than August 24, 2009.Start Signature
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E9-14705 Filed 6-22-09; 8:45 am]
BILLING CODE 4410-09-P